Treatment of Drug-resistant Pneumococcal Meningitis

Current Infectious Disease Reports
Nida Hameed, Allan R Tunkel

Abstract

The approach to therapy in patients with pneumococcal meningitis has changed considerably over the past 20 years. Given the emergence of pneumococcal strains that are intermediately susceptible or highly resistant to penicillin, penicillin is not recommended as empiric therapy for presumed pneumococcal meningitis; the combination of vancomycin and a third-generation cephalosporin (either cefotaxime or ceftriaxone) should be used, pending isolation of the organism and in vitro susceptibility testing. For patients with pneumococcal meningitis caused by highly penicillin- or cephalosporin-resistant strains, the addition of rifampin can be considered if the organism is susceptible in vitro, the expected clinical or bacteriologic response is delayed, or the pneumococcal isolate has a cefotaxime or ceftriaxone minimal inhibitory concentration greater than 4 μg/mL. Meropenem is not a good option for monotherapy of highly penicillin- or cephalosporin-resistant strains, but use of a fluoroquinolone with in vitro activity against Streptococcus pneumoniae (specifically moxifloxacin) is an option in patients failing standard therapy; if used, however, it should be combined with a third-generation cephalosporin or vancomycin. Newer glycopep...Continue Reading

References

Aug 27, 2015·Critical Care : the Official Journal of the Critical Care Forum·Cédric BretonnièreChristophe Guitton
Dec 22, 2012·Expert Opinion on Pharmacotherapy·Susanna Esposito, Nicola Principi
Jul 23, 2013·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·Lorenzo ZaffiriLuis H Toledo-Pereyra
Nov 12, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Hakan ErdemHaluk Vahaboglu
Sep 21, 2013·Inflammatory Bowel Diseases·Maneesh DaveEdward V Loftus
Sep 8, 2016·World Journal of Gastrointestinal Pharmacology and Therapeutics·Gianluca AndrisaniLuisa Guidi
Dec 7, 2011·Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·Anil K Lalwani, Noel L Cohen

Citations

Dec 1, 1991·Antimicrobial Agents and Chemotherapy·P F ViladrichJ Ariza
Feb 1, 1991·The Pediatric Infectious Disease Journal·V K WongK S Kim
Jun 1, 1994·Antimicrobial Agents and Chemotherapy·M M ParísGeorge H McCracken
Nov 5, 1997·The Pediatric Infectious Disease Journal·A Ahmed
Nov 5, 1997·The Pediatric Infectious Disease Journal·C C JohnJ R Schreiber
Jun 13, 1998·Antimicrobial Agents and Chemotherapy·H SchmidtRoland Nau
Nov 25, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·I LutsarI R Friedland
Jun 22, 1999·Nature·R NovakElaine I Tuomanen
Sep 2, 1999·Infectious Disease Clinics of North America·D R Andes, William Craig
Dec 5, 2000·The Journal of Antimicrobial Chemotherapy·Philippe CottagnoudM G Täuber
Apr 17, 2001·The Pediatric Infectious Disease Journal·Xavier Sáez-Llorens, M O'Ryan
Jan 16, 2002·The Pediatric Infectious Disease Journal·Xavier Sáez-LlorensTrovan menigitis Study Group
Jan 30, 2002·The Journal of Antimicrobial Chemotherapy·Philippe CottagnoudM G Täuber
Feb 28, 2002·The Journal of Antimicrobial Chemotherapy·J Martínez-LacasaF Gudiol
May 29, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter C Appelbaum
Jan 24, 2003·Southern Medical Journal·Steven C BuckinghamB Keith English
Oct 15, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Philippe CottagnoudJ Entenza
May 29, 2004·International Journal of Antimicrobial Agents·Hyuck LeeNam Yong Lee
Aug 11, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C N MeyerJ M Bangsborg
Aug 17, 2004·Infectious Disease Clinics of North America·Scott W Sinner, Allan R Tunkel
Sep 21, 2004·The Journal of Infectious Diseases·Carina A RodriguezElaine I Tuomanen
Oct 21, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Allan R TunkelRichard J Whitley
Dec 19, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean-Damien RicardDidier Dreyfuss
Mar 21, 2007·Antimicrobial Agents and Chemotherapy·Denis GrandgirardStephen L Leib
Mar 21, 2008·The Journal of Antimicrobial Chemotherapy·Kyriaki KanellakopoulouEvangelos J Giamarellos-Bourboulis
Apr 4, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·E ForceF Gudiol
Dec 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael RybakDonald P Levine

Related Concepts

Vancomycin
Meropenem
Fluoroquinolones
Ceftriaxone
Moxifloxacin
Vancomycin Assay
Cephalosporins
Daptomycin
Etiology
Isolate compound

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.